Abstract:Both reversible noncovalent inhibitors and irreversible covalent inhibitors targeting tyrosine kinases have their disadvantages. The reversible covalent inhibitors with electrophilic group cyanoacrylamide as warheads reacting with cysteine residues could solve the dilemmas. However, there are still several unresolved issues regarding the electrophilic groups. In this manuscript, a series of EGFR inhibitors with double electron-withdrawing substituents introduced into the C-alpha position on the olefin bond were designed and synthesized. The binding structures and characteristics of inhibitors with the kinase in both the first noncovalent binding phase and the second covalent binding step were explored and combined with molecular docking and molecular dynamics simulations. Then, the reverse beta-elimination reactions of the thiol-Michael adducts were investigated by applying density functional theory calculations. In addition, the effects of different electrophilic substituents of C-alpha on the binding between the inhibitors and kinase were elucidated. The results suggested that the electrophilicity and size of the electron-withdrawing groups play an important role in the specific interactions during the reaction. The compounds with the electron-withdrawing groups that had medium electrostatic and steric complementarity to the kinase active site could cooperatively stabilize the complexes and showed relatively good potent activities in the kinase assay experiment. The mechanical and structural information in this study could enhance our understanding of the functioning of the electron-withdrawing groups in the covalent inhibitors. The results might help to design efficient cysteine targeting inhibitors in the future.

Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Exploration of Novel Macrocyclic Dipeptide N-benzyl Amides As Proteasome Inhibitors.

Design and Synthesis of Tripeptidyl Furylketones As Selective Inhibitors Against the Β5 Subunit of Human 20S Proteasome

Covalent Docking Modelling-Based Discovery of Tripeptidyl Epoxyketone Proteasome Inhibitors Composed of Aliphatic-Heterocycles.

Design and Synthesis of A Novel Class of Furan-Based Molecules As Potential 20s Proteasome Inhibitors

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Novel CADD-based Peptidyl Vinyl Ester Derivatives As Potential Proteasome Inhibitors

Discovery of Novel Nonpeptidic Proteasome Inhibitors Using Covalent Virtual Screening and Biological Evaluation

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Design, synthesis and biological assay of novel tripeptidic tetrazoles as inhibitors of 20S proteasome

A Potent and Selective Inhibitor for the UBLCP1 Proteasome Phosphatase.

Synthesis, Bioactivity, Docking and Molecular Dynamics Studies of Furan‐Based Peptides As 20S Proteasome Inhibitors

Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment

Discovery of Novel 20S Proteasome Inhibitors by Rational Topology-Based Scaffold Hopping of Bortezomib

Discovery of a Potent and Highly Specific Β2 Proteasome Inhibitor from a Library of Copper Complexes.

Synthesis and SAR Study of Novel Peptide Aldehydes As Inhibitors of 20S Proteasome

Structural analysis and shape-based identification of novel inhibitors targeting the Trypanosoma cruzi proteasome

Synthesis and Biological Activity of Peptide Proline-Boronic Acids As Proteasome Inhibitors